Quick-Med and Foster Enter Into Joint Development Agreement

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that it has entered into a joint development agreement with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med’s proprietary NIMBUS^® technology to thermoplastics for catheters and other medical product applications.

Catheter-associated urinary tract infection is the most common nosocomial (hospital) infection. Each year, urinary catheters are inserted in more than 5 million patients in U.S. acute-care hospitals and extended-care facilities and more than 1 million of those patients acquire a catheter-associated urinary tract infection. When infection occurs, the potential medical and economic consequences can be tremendous, including increased mortality and significant additional heath care costs.

"We are excited to team with Foster Corporation to incorporate our NIMBUS technology in catheters,” said J. Ladd Greeno, CEO of Quick-Med Technologies. "Foster is a respected leader developing advanced biomedical materials to meet the requirements of medical device manufacturers. This collaboration will leverage NIMBUS technology to a next generation of antimicrobial catheters to address growing infection concerns.”

"Our partnership with Quick-Med will enable us to bring innovative, next-generation antimicrobial technology to meet the needs of both existing and potential customers,” said Dan Lazas, Foster’s Corporate Vice President, Marketing & Sales. "NIMBUS technology will continue Foster’s tradition of industry firsts by bringing much needed, uniquely effective and affordable, innovative antimicrobial protection to thermoplastic applications for the medical devices market.”

What makes NIMBUS different from other antimicrobial technology are its permanent bond and its ability to be effective even in the presence of large amounts of serum and body fluids. The active agent is permanently bonded to the substrate, keeping the biocide from depletion, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, NIMBUS continues to kill microbes outperforming other antimicrobials.

When the development is complete and FDA clearance received, management believes NIMBUS will bring safe, highly effective, and extraordinarily affordable antimicrobial protection to the $12 billion global catheter market which is projected to continue rapid growth for the next several years primarily due to the aging population.

About NIMBUS^®

NIMBUS is a next-generation wound care technology that is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. According to Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and Past President of the Wound Healing Society, "NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material. It is a novel technology: bonded and effective even in high concentrations of body fluids.”

About Foster Corporation.

For nearly 20 years, Foster Corporation has been at the forefront of developing and manufacturing state-of-the-art material solutions based on extremely precise polymer technologies, with a special focus on serving the medical, pharmaceutical delivery, and bio-technology sectors worldwide. In February 2009, Foster Corporation and Putnam Plastics Group merged to form PolyMedex Discovery Group. For more information, see: www.fostercorporation.com.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see: www.quickmedtech.com.

© 2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS^® is a registered trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and it specifically disclaims any obligation, to update any forward looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.